Blog
RSS FeedPosted by Michael Wonder on 26 Apr 2018
PHARMAC turns down DHB request for free flu vaccine for 'super spreader' kids
24 April 2018 - Health authorities are bracing for a potentially deadly flu season in New Zealand this winter after ...
Posted by Michael Wonder on 23 Apr 2018
'They make a difference' - modern medicines not being funded for Kiwis, industry group says
20 April 2018 - Nearly a quarter of a million Kiwis are missing out on the latest in modern medicine, Medicine ...
Posted by Michael Wonder on 18 Apr 2018
Terminally ill dad saves more than $200k bringing in cancer drugs from India
17 April 2018 - A Kiwi dad who's dying of lung cancer has been bypassing the PHARMAC system to get ...
Posted by Michael Wonder on 09 Apr 2018
Proposal to remove the funding restrictions for candesartan
9 April 2018 - Following assessment of bids in PHARMAC’s 2017/18 annual Invitation to Tender, PHARMAC is proposing to remove ...
Posted by Michael Wonder on 05 Apr 2018
Woman with brain tumour wants natural therapies subsidised by PHARMAC
5 April 2018 - In October 2015, Tanya Filia was told she wouldn't make Christmas due to a growing brain ...
Posted by Michael Wonder on 05 Apr 2018
Proposal to list mercaptopurine oral suspension
5 April 2018 - PHARMAC is seeking feedback on a proposal to list mercaptopurine oral solution (Allmercap) 20 mg/mL from ...
Posted by Michael Wonder on 03 Apr 2018
Relief for sufferers of neuroendocrine cancer after PHARMAC funding decision
1 April 2018 - Kiwis living with neuroendocrine cancer say they are relieved after PHARMAC recommended their treatment should be ...
Posted by Michael Wonder on 31 Mar 2018
New Zealand Pharmaceutical Schedule - 1 April 2018
1 April 2018 - The April 2018 issue of the New Zealand Pharmaceutical Schedule is now available and in effect. ...
Posted by Michael Wonder on 29 Mar 2018
Decision to list eplerenone for the treatment of heart failure
29 March 2018 - PHARMAC is pleased to announce a decision to fund eplerenone (Inspra), subject to certain clinical criteria ...
Posted by Michael Wonder on 27 Mar 2018
Proposal to fund aflibercept and rivaroxaban
27 March 2018 - PHARMAC is seeking feedback on a proposal to list aflibercept (Eylea) and rivaroxaban (Xarelto) through a ...
Posted by Michael Wonder on 26 Mar 2018
Rejected by the Government, I've spent $160,000 just to keep myself alive
25 March 2018 - Jess Spence currently pays for her Neuroendocrine cancer treatment in Melbourne, Australia. PHARMAC are still to decide ...
Posted by Michael Wonder on 15 Mar 2018
Proposal to fund denosumab for osteoporosis
16 March 2018 - PHARMAC is proposing to fund denosumab (Prolia) injections from 1 June 2018 for the treatment of severe, ...
Posted by Michael Wonder on 15 Mar 2018
Decision to open list montelukast tablets
15 March 2018 - PHARMAC will remove the Special Authority and Hospital Medicine restrictions on montelukast 4 mg, 5 mg ...
Posted by Michael Wonder on 15 Mar 2018
PHARMAC publishes indicative agenda for May 2018 PTAC meeting
15 March 2018 - The May 2018 PTAC meeting will review the following applications for several new medicines. ...
Posted by Michael Wonder on 11 Mar 2018
Proposal to widen access and change the funded brand of tenofovir disoproxil and entecavir
9 March 2018 - PHARMAC is delighted to propose the widening of access to tenofovir disoproxil and entecavir, anti-viral medicines ...